Acura Pharmaceuticals
ACUR
ACUR was delisted on the 22nd of February, 2017.
28 hedge funds and large institutions have $8.96M invested in Acura Pharmaceuticals in 2014 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 8 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
15% less funds holding
Funds holding: 33 → 28 (-5)
25% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 8
29% less capital invested
Capital invested by funds: $12.6M → $8.96M (-$3.64M)
63% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$30.2K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$13.1K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$10.8K |
| 4 |
SIM
Spark Investment Management
New York
|
+$10.5K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.15K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Hodges Capital Management
Dallas,
Texas
|
-$32K |
| 2 |
Jane Street
New York
|
-$18K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$18K |
| 4 |
OC
Oppenheimer & Co
New York
|
-$16K |
| 5 |
Creative Planning
Overland Park,
Kansas
|
-$14.6K |
ACUR Hedge Fund Activity: Q3 2014 in Review
28 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Acura Pharmaceuticals (ACUR) for Q3 2014, worth a combined $8.96M — down 29% from $12.6M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of ACUR and 3 opened new positions — a net loss of 5 holders — while 8 trimmed existing stakes and 6 added.
The largest buyer was Renaissance Technologies, adding an estimated $30.2K. The largest seller was Hodges Capital Management, exiting entirely with an estimated $32K sold.
- 28 institutional investors held Acura Pharmaceuticals (ACUR) as of Q3 2014, down from 33 in Q2 2014.
- Funds reported $8.96M of Acura Pharmaceuticals stock for Q3 2014, down 29% quarter-over-quarter.
- 3 funds opened new Acura Pharmaceuticals positions in Q3 2014 and 8 closed out, a net change of -5 holders.
- The largest Acura Pharmaceuticals buyer in Q3 2014 was Renaissance Technologies, an estimated $30.2K added.
- The largest Acura Pharmaceuticals seller in Q3 2014 was Hodges Capital Management, an estimated $32K sold.
Based on aggregated 13F filings for Q3 2014.